Christina Trojacher

Mrs. Christina Trojacher


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MGMartha Gschwandtner
Martha Gschwandtner
RDRupert Derler
Rupert Derler
ETElisa Talker
Elisa Talker
CTChristina Trojacher
Christina Trojacher
NGNina Gubensäk
Nina Gubensäk
AKAndreas Kungl
Andreas Kungl
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized. Generating glycan-specific antibodies is difficult due to their size, pattern dispersion, and flexibility. Single-domain variable new antigen receptors (VNAR nanobodies) from nurse sharks are highly soluble, stable, and versatile. Their unique properties suggest advantages over conventional antibodies, particularly for challenging biotherapeutic targets. Here we have used VNAR semi-synthetic phage libraries to select high-affinity fondaparinux-binding VNARs that did not show cross-reactivity with other GAG species. Competition ELISA and surface plasmon resonance identified a single fondaparinux-selective VNAR clone. This VNAR exhibited an extraordinarily stable protein fold: the beta-strands are stabilized by a robust hydrophobic network, as revealed by heteronuclear NMR. Docking fondaparinux to the VNAR structure revealed a large contact surface area between the CDR3 loop of the antibody and the glycan. Fusing the VNAR with a human Fc domain resulted in a stable product with a high affinity for fondaparinux (Kd = 9.3 × 10−8 M) that could efficiently discriminate between fondaparinux and other glycosaminoglycans. This novel glycan-targeting screening technology represents a promising therapeutic strategy for addressing GAG-related diseases.

26 December 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
FBFabio Beretta
Fabio Beretta
LALotte Agten
Lotte Agten
VOVivian Louise Soares de Oliveira
Vivian Louise Soares de Oliveira
NBNele Berghmans
Nele Berghmans
CTChristina Trojacher
Christina Trojacher
AKAndreas Kungl
Andreas Kungl
Chemokines are essential immune regulators that interact with G protein-coupled receptors (GPCRs) on leukocytes and with glycosaminoglycans (GAGs) on the surface of endothelial cells to form a chemotactic gradient, essential for directional leukocyte migration. The chemokine CXCL9 contains multiple C-terminal GAG-binding motifs, responsible for the high affinity of the protein to endothelial GAGs. Through chemical synthesis of CXCL9's C-terminal domain, composed of the last 30 amino acids of the sequence, we generated the GAG-binding chemotaxis antagonist CXCL9(74-103). This peptide is able to bind GAGs on the endothelial surface, but fails to elicit a chemotactic response. As such, it appeared to be an effective anti-inflammatory compound, dampening leukocyte infiltration and tissue damage without increasing pathogen load. However, the therapeutic applications of CXCL9(74-103) are limited due to its rapid renal clearance, a well-known drawback of peptide-based therapeutics. This study explores the use of human serum albumin (HSA) as a fusion scaffold to extend the serum half-life and thus improve the anti-inflammatory properties of CXCL9(74-103). This HSA-CXCL9(74-103) fusion protein was produced in Pichia pastoris for biochemical, pharmacological and functional characterization. The GAG-binding affinity was assessed by isothermal fluorescence titration and surface plasmon resonance experiments. Bioavailability experiments following i.v. injection in C57BL/6JRj mice demonstrated prolonged blood half-life of our fusion protein, as well as stronger reduction of leukocyte recruitment to inflamed joints, both acutely and over an extended period of time. These findings show that HSA-CXCL9(74-103) has substantial potential as a long-lasting anti-inflammatory therapeutic, offering improved pharmacokinetics and sustained efficacy.